Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells

Takeshi Sugimoto1, Chandra Bartholomeusz, Ana M Tari

  • 1Breast Cancer Translational Research Laboratory, The University of Texas M, D, Anderson Cancer Center, Houston, TX, USA. tks_sugimoto@yahoo.co.jp.

Abstract

Insights

Celecoxib enhances adenovirus E1A-induced apoptosis in cancer cells by suppressing cyclooxygenase-2 (COX-2). This strategy may overcome resistance to E1A gene therapy by blocking prostaglandin pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Suppression of Bcl-2 can overcome resistance to adenovirus type 5 gene E1A-induced apoptosis in ovarian and breast cancers.
  • Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, downregulates Bcl-2 expression.
  • This study investigates if celecoxib enhances E1A-induced apoptosis by suppressing Bcl-2 via COX-2 inhibition.

Purpose of the Study:

  • To determine if celecoxib enhances E1A-induced apoptosis in cancer cells.
  • To investigate the role of cyclooxygenase-2 (COX-2) and Bcl-2 in celecoxib's effect.
  • To explore potential mechanisms for overcoming resistance to E1A gene therapy.

Main Methods:

  • Cytotoxicity assays of celecoxib in E1A-transfected breast and ovarian cancer cell lines with varying COX-2 expression.
  • Flow cytometry and western blotting to assess apoptosis and Bcl-2 suppression.
  • Investigating the role of prostaglandin E2 (PGE2) and PGF2alpha in celecoxib sensitivity.

Main Results:

  • COX-2-overexpressing cell lines were more sensitive to celecoxib than low-COX-2-expressing lines.
  • Celecoxib increased apoptosis markers (PARP, caspase-9) in sensitive cell lines.
  • Bcl-2 suppression was observed only in one cell line; restoring Bcl-2 did not affect sensitivity.
  • Prostaglandins PGE2 or PGF2alpha blunted celecoxib sensitivity.

Conclusions:

  • Celecoxib enhances E1A-induced apoptosis in cancer cells with high COX-2 expression.
  • A potential mechanism involves blocking prostaglandin pathways (PGE2/PGF2alpha).
  • This approach may help overcome resistance to E1A gene therapy.

Related Concept Videos

Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...